Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Torii Enjoys Stellar Performance from Corectim, 1st JAK Med for Atopic Dermatitis
Torii Pharmaceutical’s new atopic dermatitis (AD) treatment Corectim (delgocitinib), the world’s first topical JAK inhibitor, is ringing up a strong uptake in Japan, with the drug likely to be one of the next pillars of the Japan Tobacco subsidiary after…
To read the full story
Related Article
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Yoshindo Eyes Biosimilar API Production from 2028 with Cytiva Support
April 2, 2026
- Nippon Kayaku to Buy Fuji Yakuhin’s Injectable Plant in Japan
April 2, 2026
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…